Lexipafant

Lexipafant (BB-882, Zacutex) is a drug which acts as a potent and selective inhibitor of the phospholipid mediator platelet-activating factor (PAF). It was developed in the 1990s by British Biotech with several potential applications, including HIV-associated neurocognitive disorder and acute pancreatitis. Initial results were encouraging and it progressed as far as Phase III clinical trials, but final analysis of trial results showed that it failed to improve survival rates in pancreatitis despite some symptomatic improvement, and it was ultimately discontinued from development as a medicine, though it continues to be used as a model PAF inhibitor for pharmacology research.^[1][2][3][4]

CAS Number

• 139133-26-9

PubChem CID

• 9804204

ChemSpider

• 7979964

UNII

• H14917M9YW

Quick facts Identifiers, CAS Number ...

Lexipafant

Identifiers
IUPAC name ethyl (2S)-4-methyl-2-[methyl-[4-[(2-methylimidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonylamino]pentanoate
CAS Number	139133-26-9
PubChem CID	9804204
ChemSpider	7979964
UNII	H14917M9YW
ChEMBL	ChEMBL322832
CompTox Dashboard (EPA)	DTXSID701318348
Chemical and physical data
Formula	C23H30N4O4S
Molar mass	458.58 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOC(=O)C(CC(C)C)N(C)S(=O)(=O)C1=CC=C(C=C1)CN2C(=NC3=C2C=CN=C3)C
InChI InChI=1S/C23H30N4O4S/c1-6-31-23(28)22(13-16(2)3)26(5)32(29,30)19-9-7-18(8-10-19)15-27-17(4)25-20-14-24-12-11-21(20)27/h7-12,14,16,22H,6,13,15H2,1-5H3/t22-/m0/s1 Key:AQRXDPFOYJSPMP-QFIPXVFZSA-N

Close